Cogent Biosciences logo
COGTCogent Biosciences
Trade COGT now
Cogent Biosciences primary media

About Cogent Biosciences

Cogent Biosciences (NASDAQ:COGT) is a biotechnology company focused on developing precision therapies for genetically defined diseases. Their main projects involve creating innovative treatments that can significantly improve the lives of patients with serious conditions by targeting the underlying genetic causes of these diseases. With a passionate commitment to science and patient care, Cogent Biosciences aims to bring forth novel medicines that offer better efficacy and safety profiles. Their objective is to transform the treatment landscape for conditions currently lacking effective therapies, thereby addressing unmet medical needs and enhancing patient outcomes.

What is COGT known for?

Snapshot

Public US
Ownership
2014
Year founded
164
Employees
Waltham, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Waltham, US

Produtos e/ou serviços de Cogent Biosciences

  • A precision therapy targeting specific mutations in gastrointestinal stromal tumors (GIST).
  • A novel treatment designed for mastocytosis, focusing on mutations that drive the disease.
  • Development of therapies for resistant and difficult-to-treat forms of leukemia.
  • A comprehensive diagnostic tool to identify specific mutations in cancers for personalized treatment plans.
  • Research collaborations aimed at discovering novel oncology targets and developing targeted therapies.
  • Participation in global clinical trials to expand the knowledge and application of precision medicine in oncology.

equipe executiva do Cogent Biosciences

  • Mr. Andrew R. Robbins M.B.A.President, CEO & Director
  • Mr. John L. Green C.A., CPACFO & Principal Accounting Officer
  • Dr. John Edward Robinson Ph.D.Chief Scientific Officer
  • Dr. Jessica Sachs M.D.Chief Medical Officer
  • Mr. Cole PinnowChief Commercial Officer
  • Mr. Brad BarnettChief Technology Officer
  • Ms. Christi WaarichSenior Director of Investor Relations
  • Mr. Evan D. Kearns J.D.Chief Legal Officer & Corporate Secretary
  • Mr. Abb HaydenSenior Vice President of Sales
  • Ms. Erin SchellhammerChief People Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.